Connect with others who understand.

Sign up Log in
Resources
About MyLeukemiaTeam
Powered By
Real members of MyLeukemiaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

Is Anyone On An Obinutuxumab/Vanclexta Regimen For CLL? Anyone Have A Treatment-resistant Gene (q17)? If So, Please Share How It’s Going.

A MyLeukemiaTeam Member asked a question 💭
Woodbury, MN
August 8, 2024
View reactions
A MyLeukemiaTeam Member

We need to stay positive and do what we can. 🙏🏻🙏🏻

August 11, 2024
A MyLeukemiaTeam Member

I’m sorry to hear that. I have 6 months of monthly infusions (obinutiuxumab) and am now on 400 mg per day of Venclexta. I’ve had some dizziness, and I had a very low hemoglobin (5.9), which blood transfusions did not help. My hemoglobin is now 7.5 and my WBC has gone down, which is good. Apparently it’s a wait and see game for the next 30 days to hope for more improvements. I have hemolytic anemia too, and a splenectomy is one possibility if my red cells don’t improve. I B was diagnosed 14 years ago and have had four rounds of regular chemo (one of which gave me a 6 year remission. Now the q17 gene is showing up in over 90% of my cells, so that’s an added challenge. My prognosis has suffered but I have an oncologist I trust so it’s one month at a time (from blood test to blood test). Good luck to you!

August 8, 2024
A MyLeukemiaTeam Member

Obinutuzumab and Venclexta (venetoclax) are used in combination to treat chronic lymphocytic leukemia (CLL). This combination can be particularly useful for people with certain genetic mutations, such as del(17p) or TP53 mutations, which make CLL more difficult to treat with traditional chemotherapy.

Key Points
- Show Full Answer

Obinutuzumab and Venclexta (venetoclax) are used in combination to treat chronic lymphocytic leukemia (CLL). This combination can be particularly useful for people with certain genetic mutations, such as del(17p) or TP53 mutations, which make CLL more difficult to treat with traditional chemotherapy.

Key Points:
- Obinutuzumab: A monoclonal antibody that targets cancer cells.
- Venclexta (venetoclax): A BCL-2 inhibitor that helps cancer cells self-destruct.

Considerations:
- Genetic Mutations: CLL with del(17p) or TP53 mutations often does not respond well to traditional chemotherapy, making targeted therapies like Venclexta more effective.
- Side Effects: Venclexta can cause side effects such as anemia, neutropenia, diarrhea, and nausea. A serious side effect is tumor lysis syndrome, which may require hospitalization.

For those with treatment-resistant genes like del(17p), this regimen can be a promising option. Always consult with your healthcare provider for personalized advice.

August 8, 2024
A MyLeukemiaTeam Member

I was on Venclexta before and during my chemo treatments . Once my Chemo treatments were concluded I was taken off Venclexta . I have defiantly had after effects either from the chemo and possibly the Venclexta . I have never been told by my Cancer team which after effects were caused by either one . I still have symptoms such as insomnia , headaches , severe loss of energy , and irregular bowel movements ,I also suffer from memory loss imbalance and a low apatite . .

August 8, 2024

Related content

View All

Has Anyone Been On The Oral Chemo Called Ingovi, Or Venetoclax? My Oncologist Is Also Putting Me On Antibiotics And Anti-fungals.

A MyLeukemiaTeam Member asked a question 💭
Rochester, NY

Has Anyone Been On Gazyva & Venclexta? What Side Effects Did You Experience?

A MyLeukemiaTeam Member asked a question 💭

I’m Taking Imbruvica For CLL. Can Venetoclax And Obinutuzumab Be Used In Previously Treated Patients And If So, For How Long Taken?

A MyLeukemiaTeam Member asked a question 💭
Marble Falls, TX
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data Policy and Privacy policies.Your privacy is our priority Lock Icon
Already a Member? Log in